Sarah B. Goldberg

机构：Yale Cancer Center, Yale University, Medical Oncology Hematology Consultants · ORCID：0000-0002-0920-1381

发表论文 512 篇 · 总被引 13394 次 · h-index 50

代表论文

• Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD (2026 · Lung Cancer · 被引 2)
• ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer (2026 · Journal of Thoracic Oncology · 被引 2)
• Osimertinib Plus Gefitinib in Patients with EGFR -Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD (2026 · Clinical Cancer Research · 被引 1)
• Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD (2026 · European Journal of Cancer · 被引 1)
• Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study (2026 · Clinical Cancer Research · 被引 1)
• Treatment of Non–Small Cell Lung Cancer (2026 · The Cancer Journal)